Human Pancreatic Secretory Trypsin Inhibitor Stabilizes Intestinal Mucosa Against Noxious Agents

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2007 Nov 6

PMID 17982125

Citations 3

Authors

Tania Marchbank

Asif Mahmood

Anthony J Fitzgerald

Jan Domin

Matt Butler

Robert A Goodlad

George Elia

Helen M Cox

David A van Heel

Subrata Ghosh

Raymond J Playford

Affiliations

Soon will be listed here.

Abstract

Pancreatic secretory trypsin inhibitor (PSTI) is a serine protease inhibitor, expressed in gut mucosa, whose function is unclear. We, therefore, examined the effects of PSTI on gut stability and repair. Transgenic mice overexpressing human PSTI within the jejunum (FABPi(-1178 to +28) hPSTI construct) showed no change in baseline morphology or morphometry but reduced indomethacin-induced injury in overexpressing hPSTI region by 42% (P < 0.01). Systemic recombinant hPSTI did not affect baseline morphology or morphometry but truncated injurious effects in prevention and recovery rat models of dextran-sodium-sulfate-induced colitis. In vitro studies showed PSTI stimulated cell migration but not proliferation of human colonic carcinoma HT29 or immortalized mouse colonic YAMC cells. PSTI also induced changes in vectorial ion transport (short-circuit current) when added to basolateral but not apical surfaces of polarized monolayers of Colony-29 cells. Restitution and vectorial ion transport effects of PSTI were dependent on the presence of a functioning epidermal growth factor (EGF) receptor because cells with a disrupted (EGFR(-/-) immortalized cells) or neutralized (EGFR blocking antibodies or tyrosine kinase inhibitor) receptor prevented these effects. PSTI also reduced the cytokine release of lipopolysaccharide-stimulated dendritic cells. We conclude that administration of PSTI may provide a novel method of stabilizing intestinal mucosa against noxious agents and stimulating repair after injury.

Citing Articles

Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials.

Playford R, Cattell M, Marchbank T PLoS One. 2020; 15(6):e0234719.

PMID: 32555629 PMC: 7299325. DOI: 10.1371/journal.pone.0234719.

Pancreatic secretory trypsin inhibitor reduces multi-organ injury caused by gut ischemia/reperfusion in mice.

Playford R, Marchbank T PLoS One. 2020; 15(1):e0227059.

PMID: 31923181 PMC: 6953855. DOI: 10.1371/journal.pone.0227059.

Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.

Wang G, Xu C World J Gastrointest Pathophysiol. 2011; 1(2):85-90.

PMID: 21607145 PMC: 3097947. DOI: 10.4291/wjgp.v1.i2.85.

References

Marchbank T, Chinery R, Hanby A, Poulsom R, Elia G, Playford R . Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution. Am J Pathol. 1996; 148(3):715-22. PMC: 1861739. View

Freeman T, Playford R, Quinn C, Beardshall K, Poulter L, Young J . Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut. 1990; 31(11):1318-23. PMC: 1378707. DOI: 10.1136/gut.31.11.1318. View

Calnan D, Westley B, May F, Floyd D, Marchbank T, Playford R . The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol. 1999; 188(3):312-7. DOI: 10.1002/(SICI)1096-9896(199907)188:3<312::AID-PATH360>3.0.CO;2-P. View

Egger B, Bajaj-Elliott M, MacDonald T, Inglin R, Eysselein V, Buchler M . Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion. 2000; 62(4):240-8. DOI: 10.1159/000007822. View

Hibi T, Ogata H, Sakuraba A . Animal models of inflammatory bowel disease. J Gastroenterol. 2002; 37(6):409-17. DOI: 10.1007/s005350200060. View

Chinery R, Cox H . Modulation of epidermal growth factor effects on epithelial ion transport by intestinal trefoil factor. Br J Pharmacol. 1995; 115(1):77-80. PMC: 1908733. DOI: 10.1111/j.1476-5381.1995.tb16322.x. View

Playford R, Hanby A, Patel K, Calam J . Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon. Am J Pathol. 1995; 146(2):310-6. PMC: 1869860. View

Playford R, Hanby A, Gschmeissner S, Peiffer L, Wright N, McGarrity T . The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract. Gut. 1996; 39(2):262-6. PMC: 1383309. DOI: 10.1136/gut.39.2.262. View

Marchbank T, Cox H, Goodlad R, Giraud A, Moss S, Poulsom R . Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. J Biol Chem. 2001; 276(26):24088-96. DOI: 10.1074/jbc.M101363200. View

10.

Levi S, Shaw-Smith C . Non-steroidal anti-inflammatory drugs: how do they damage the gut?. Br J Rheumatol. 1994; 33(7):605-12. DOI: 10.1093/rheumatology/33.7.605. View

11.

Marchbank T, Westley B, May F, Calnan D, Playford R . Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol. 1998; 185(2):153-8. DOI: 10.1002/(SICI)1096-9896(199806)185:2<153::AID-PATH87>3.0.CO;2-5. View

12.

Niinobu T, Ogawa M, Shibata T, Murata A, Nishibe S, Mori T . Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol. 1986; 53(2):245-8. View

13.

Scheving L . Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys. 1983; 226(2):411-3. DOI: 10.1016/0003-9861(83)90309-0. View

14.

Cooper H, Murthy S, Shah R, Sedergran D . Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69(2):238-49. View

15.

El Sheikh S, Domin J, Abel P, Stamp G, Lalani E . Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia. 2005; 6(6):846-53. PMC: 1531689. DOI: 10.1593/neo.04379. View

16.

Cohn S, Simon T, Roth K, Birkenmeier E, Gordon J . Use of transgenic mice to map cis-acting elements in the intestinal fatty acid binding protein gene (Fabpi) that control its cell lineage-specific and regional patterns of expression along the duodenal-colonic and crypt-villus axes of the gut.... J Cell Biol. 1992; 119(1):27-44. PMC: 2289640. DOI: 10.1083/jcb.119.1.27. View

17.

Williams K, Fuller C, Dieleman L, DaCosta C, Haldeman K, Sartor R . Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology. 2001; 120(4):925-37. DOI: 10.1053/gast.2001.22470. View

18.

Marks W, Ohlsson K . Elimination of pancreatic secretory trypsin inhibitor from the circulation. A study in man. Scand J Gastroenterol. 1983; 18(7):955-9. DOI: 10.3109/00365528309182122. View

19.

Whitehead R, VanEeden P, Noble M, Ataliotis P, Jat P . Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci U S A. 1993; 90(2):587-91. PMC: 45708. DOI: 10.1073/pnas.90.2.587. View

20.

Ohmuraya M, Hirota M, Araki M, Mizushima N, Matsui M, Mizumoto T . Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice. Gastroenterology. 2005; 129(2):696-705. DOI: 10.1016/j.gastro.2005.05.057. View